Patrycja Rzepka-Wrona

Dr. Patrycja Rzepka-Wrona

Medical University of Silesia, Katowice, Śląskie, Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EMEwa Miądlikowska
Ewa Miądlikowska
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
JMJoanna Milkowska-Dymanowska
Joanna Milkowska-Dymanowska
ABAdam Białas
Adam Białas
Wojciech PiotrowskiWojciech Piotrowski
Wojciech Piotrowski
Interstitial pneumonia with autoimmune features (IPAF) belongs to a group of diseases called interstitial lung diseases (ILDs), which are disorders of a varied prognosis and course. Finding sufficiently specific and sensitive biomarkers would enable the progression to be predicted, the natural history to be monitored and patients to be stratified according to their treatment. To assess the significance of pulmonary fibrosis biomarkers studied thus far, we searched the PubMed, Medline and Cochrane Library databases for papers published between January 2015 and June 2021. We focused on circulating biomarkers. A primary review of the databases identified 38 articles of potential interest. Overall, seven articles fulfilled the inclusion criteria. This review aims to assess the diagnostic and prognostic value of molecules such as KL-6, SP-A, SP-D, circulating fibrocytes, CCL2, CXCL13, CXCL9, CXCL10 and CXCL11. All of these biomarkers have previously been studied in idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). IPAF is a disorder of a heterogeneous nature. It explains the lack of coherent observations in terms of correlations with functional parameters. There is still no meta-analysis of pulmonary fibrosis biomarkers in IPAF. This is mainly due to the heterogeneity of the methodology and groups analysed in the research. More research in this area is needed.

3 June 2018 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
SSSzymon Skoczynski
Szymon Skoczynski
DWDawid Wrona
Dawid Wrona
ABAdam Barczyk
Adam Barczyk
The administration of aerosolized medication is a basic therapy for patients with numerous respiratory tract diseases, including obstructive airway diseases (OADs), cystic fibrosis (CF), and infectious airway diseases. The management and care for patients requiring mechanical ventilation remains one of the greatest challenges for medical practitioners, both in intensive care units (ICUs) and pulmonology wards. Aerosol therapy is often necessary for patients receiving noninvasive ventilation (NIV), which may be stopped for the time of drug delivery and administered through a metered-dose inhaler or nebulizer in the traditional way. However, in most severe cases, this may result in rapid deterioration of the patient’s clinical condition. Unfortunately, only limited number of original well-planned studies addressed this problem. Due to inconsistent information coming from small studies, there is a need for more precise data coming from large prospective real life studies on inhalation techniques in patients receiving NIV.

Verified
Journal Article
Open access
PDF file
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
SSSzymon Skoczynski
Szymon Skoczynski
Adam BarczykAdam Barczyk
Adam Barczyk
In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial pneumonia with autoimmune features (IPAF), connective-tissue-disease-associated interstitial lung diseases (CTD-ILDs), and idiopathic interstitial pneumonias (IIPs). Forty participants were recruited: 9 with IPAF, 15 with CTD-ILDs, and 16 with IIPs. Concentration of transforming growth factor beta (TGF-β1), surfactant proteins A and D (SP-A, SP-D), interleukin 8 (IL-8), and chemokine 1 (CXCL1) were assessed with ELISA assay in bronchoalveolar lavage (BAL) fluid. We revealed that IL-8 and TGF-β1 concentrations were significantly lower in the IPAF group than in the CTD-ILD group (p = 0.008 and p = 0.019, respectively), but similar to the concentrations in the IIP group. There were significant correlations of IL-8 (rs = 0.46; p = 0.003) and CXCL1 (rs = 0.52; p = 0.001) and BAL total cell count (TCC). A multivariate regression model revealed that IL-8 (β = 0.32; p = 0.037) and CXCL1 (β = 0.45; p = 0.004) are significant predictors of BAL TCC. We revealed that IL-8 and TGF-β1 BAL concentrations vary in patients with different ILDs and found that IL-8 is a predictor of BAL TCC in IPAF. However, this needs to be confirmed in a multicenter cooperative study (ClinicalTrials.gov Identifier: NCT03870828).

1 June 2022 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
EMEwa Miądlikowska
Ewa Miądlikowska
SSSzymon Skoczyński
Szymon Skoczyński
ABAdam Barczyk
Adam Barczyk
WPWojciech Piotrowski
Wojciech Piotrowski
Background and Objective: Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 as a research statement of European Respiratory Society and American Thoracic Society. Connective tissue diseases (CTDs) manifest in the respiratory tract, the main manifestation being interstitial lung disease, which contributes to morbidity and mortality. This poses numerous clinical challenges and is a substantial burden on healthcare systems around the world. The objective of this narrative review was to provide readers with a comprehensive and extensive overview of such manifestations in the respiratory system, analysis of prevalence of specific manifestations in the lung and to characterize population of patients with IPAF. Methods: We reviewed the current state of knowledge on radiological findings in interstitial lung diseases in course of convective tissue diseases and IPAF, a narrative review of PubMed database using Advanced Search Builder was performed. The search was conducted from 15.07.2021 to 03.04.2022. A total of 655 articles in English were reviewed. Key Content and Findings: Similarities and differences between interstitial pneumonia in course of well-established CTDs and IPAF are discussed with special emphasis on required future research areas. Manifestations of CTDs in the respiratory system are overviewed, with the emphasis on interstitial lung disease, as despite clinical similarities of various connective tissue diseases, there is variability in their presentation in the respiratory system, radiological patterns and clinical outcomes. We would also like to draw readers’ attention to clinical significance of interstitial lung abnormality both in the context of CTDs and lack of underlying autoimmune disorders. Conclusions: There is need for prospective cohort studies regarding the natural course of IPAF, its clinical stability and its manifestations in the respiratory system. Prospective studies are also required to evaluate diagnostic and prognostic factors of IPAF. Interstitial lung disease associated with CTDs (CTD-ILD) is a significant factor impacting clinical outcomes and patient prognosis, therefore its diagnostic work-up is best performed by an experienced multidisciplinary team and with use of procedures of high diagnostic yield.

17 November 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
SSSzymon Skoczynski
Szymon Skoczynski
Wojciech PiotrowskiWojciech Piotrowski
Wojciech Piotrowski
EJEwa Jassem
Ewa Jassem
Dariusz Idzi ZioraDariusz Idzi Ziora
Dariusz Idzi Ziora
Adam BarczykAdam Barczyk
Adam Barczyk
Background: “Interstitial lung disease” (ILD) is a broad term encompassing diseases of different backgrounds. “Interstitial pneumonia with autoimmune features” (IPAF) is a recent term that implies the presence of autoimmunity. Objective: This study aims to determine the characteristics of Polish patients with IPAF, compare them with patients with other interstitial pneumonias, and search for the prognostic and diagnostic biomarkers of IPAF in serum and bronchoalveolar lavage fluid (BALF). Methods: This multicenter prospective study plans to recruit 240 participants divided into 1 study group and 2 control groups. Biological fluid samples will be collected according to Polish Respiratory Society management guidelines and stored at –80°C for further tests. Prospective 5-year observations of 60 newly diagnosed individuals are planned. The study will be divided into subsections. First, we plan to characterize Polish patients with IPAF (study group) against their peers with other ILDs (2 control groups). Control group 1 will comprise patients with idiopathic ILDs, including mainly idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Control group 2 will comprise patients with connective tissue disease–associated interstitial lung diseases, such as rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, Sjögren’s syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Radiological and functional parameters will be analyzed. Patients will be compared in terms of high-resolution computed tomography results, the 6-minute walking test performance, and pulmonary function test parameters. The diagnosis of IPAF will be reassessed on a regular basis through multidisciplinary discussion in order to determine its clinical stability. In the laboratory arm, inflammation and fibrosis pathways will be assessed. Cytokine levels (interleukin 8, transforming growth factor beta 1, chemokine C-C motif ligand [CXCL]18, CXCL1, surfactant protein [SP]-A, SP-D, Krebs von den Lungen-6 protein, and chitinase 1) will be measured in serum and BALF. A comparative analysis of serum and BALF cytokine levels will be performed in order to establish potential differences between systemic and local inflammatory pathways. In the quality of life (QoL) arm of the study, dyspnea and cough and their impact on various aspects of the QoL will be assessed. Depression and anxiety will be measured with the Hospital Anxiety and Depression Modified Scale and the 9-item Patient Health Questionnaire, and potential correlations with symptom prevalence will be assessed. Results: This study will start recruiting patients to phase 1 in October 2023. The final results will be available in 2028. We plan to publish preliminary results after 2-3 years from the start of phase 1. Conclusions: This study will be a step toward a better understanding of IPAF etiopathogenesis and outcomes. International Registered Report Identifier (IRRID): PRR1-10.2196/44802

20 May 2026 in JMIR Formative Research
Verified
Journal Article
Open access
PRPatrycja Rzepka-Wrona
Patrycja Rzepka-Wrona
MSMarzena Trzaska Sobczak
Marzena Trzaska Sobczak
Adam BarczykAdam Barczyk
Adam Barczyk
SSSzymon Skoczynski
Szymon Skoczynski
Background: Quality of life (QOL) is an important aspect of every chronic disease, including interstitial lung disease (ILD). QOL is perceived as a significant patient-centered outcome. Objective: This study aims to identify factors correlating with different aspects of QOL in patients with various ILDs. Methods: We recruited 57 participants hospitalized in a tertiary care clinical center to this pilot observational cross-sectional study. These included 22 patients with idiopathic interstitial pneumonia (IIP), 19 patients with connective tissue disease–associated ILD (CTD-ILD), and 16 patients with interstitial pneumonia with autoimmune features (IPAF). The Saint George’s Respiratory Questionnaire (SGRQ) and World Health Organization Quality of Life Questionnaire (WHOQOL-BREF) were used to assess QOL, and the Hospital Anxiety and Depression Scale - Modified Version (HADS-M) and Patient Health Questionnaire - 9 (PHQ-9) were used to evaluate depression severity. Functional parameters including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV 1 ), transfer lung capacity for carbon monoxide (TLCO), and 6-minute walk distance (6MWD) were assessed. Assessment of QOL was a secondary outcome measure in a multicenter prospective study aimed at determining the characteristics of Polish patients with interstitial pneumonia with autoimmune features. Results: In each study group, positive correlations existed between the WHOQOL-BREF physical domain score and FEV 1 % predicted value ( P =.001) and TLCO % predicted value ( P =.03). Regardless of diagnosis, higher depression, anxiety, and aggression scores (ie, worse mental health) correlated negatively with multiple domains of QOL measured using the WHOQOL-BREF. Predictors of QOL aspects varied in each study group. In the IPAF group, the TLCO % predicted value was a predictor of QOL expressed as the SGRQ total score ( P =.005). In the CTD-ILD group, short 6MWD ( P <.001) and high HADS-M aggression score ( P =.01) correlated with low QOL (expressed as a high SGRQ total score). In the IIP group, 6MWD ( P =.002) and PHQ-9 scores ( P <.001) were predictors for SGRQ symptoms score. Gender-based differences were revealed: In all study groups, men had higher scores in the psychological, social, and environmental domains of the WHOQOL-BREF, indicating better QOL, without a statistically significant difference in the physical domain scores between genders. Diagnosis-based differences in the psychological aspects of QOL were also revealed: The QOL psychological domain scores were significantly lower in the CTD-ILD and IPAF groups than in the IIP group, indicating worse QOL ( P =.01). Conclusions: QOL is a multifaceted issue with various factors impacting its assessment. 6MWD, TLCO predicted value, and worse functional ability might specifically impact QoL in ILD. Mental health is an important aspect of QOL in the ILD population, as patients with a chronic, potentially life-limiting disease may be more prone to developing depression or anxiety. Assessment of QOL should be taken into account in clinical decision-making and research on chronic diseases, as this patient-related outcome may impact therapeutic decisions and patient compliance.